FDA Approves Unknown Drug — INGENUS PHARMS NJ

INGENUS PHARMS is expected to see a positive impact on its consolidated sales following the receipt of FDA approval for its generic equivalent under ANDA215584, which strengthens its position within the specific qualifying product space just ahead of the February 7 launch date. This regulatory clearance allows the New Jersey-based company to advance toward market exclusivity, providing an anticipated revenue stream as it competes against the innovator brand.